- CareDx (CDNA) has surged 300% over the past year, driven by robust technical momentum and strong buy signals.
- CDNA is rated a “Strong Buy” by several analysts, with consensus price targets suggesting up to 12% further upside.
- Revenue is projected to grow 30.38% this year, with earnings expected to rise 109.19%, supporting the bullish outlook.
- Technical indicators remain bullish, but high volatility and a trailing price-earnings ratio highlight speculative risk.